Drugs / SARS-Cov-2 Vaccine Inactivated
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04508075 | Aug 2020 → Jan 2021 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05238649 Comparator | Nov 2021 → Nov 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 vaccine (inactivated) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04508075 ↗ |
| Modality | Vaccine | “SARS-CoV-2 vaccine (inactivated)” NCT04508075 ↗ |
| Route | Intramuscular | “Participants receive 2 doses of SARS-CoV-2 Inactivated Vaccine with 14 days interval, intramuscularly” NCT04508075 ↗ |